Why are Ocugen (OCGN), BioNTech (BNTX) stocks in focus?

Follow us on Google News:
 Why are Ocugen (OCGN), BioNTech (BNTX) stocks in focus?
Image source: ra2 studio,Shutterstock


  • Ocugen, Inc. (NASDAQ: OCGN) had cash, cash equivalents, and restricted cash of US$115.8 million in Q2, FY21.
  • The OCGN stock surged 132.9 percent YTD.
  • BioNTech SE (NASDAQ: BNTX) reported a net profit of €2.78 billion in Q2, FY21.

The stocks of Ocugen, Inc. (NASDAQ: OCGN) and BioNTech SE (NASDAQ: BNTX) were trending on Wall Street Monday. The former rose more than 19 percent, and the latter declined around 6 percent in intraday trading.

The OCGN stock was priced at US$8.56 at 1:29 pm ET, up 19.72 percent, while BNTX stock traded at US$327.685 at 1:31 pm ET, down 6.16 percent from their previous close.

Let's look at some of the recent developments of the two companies.

Also Read: Will these 5 travel stocks survive as Delta variant saps confidence?

Ocugen, Inc. (NASDAQ: OCGN)

Ocugen, Inc. is a biopharma company based in Pennsylvania. It develops gene therapies for various diseases. Besides, it is also developing a Covid-19 vaccine in collaboration with the Indian company Bharat Biotech.

In December 2020, it partnered with Bharat Biotech to develop Covaxin. The World Health Organization (WHO) is expected to approve the vaccine for emergency use listing (EUL).

On July 9, the companies had submitted the required documents concerning the vaccine to WHO, Bharat Biotech chairman and MD Krishna Ella said.

Also Read: DBS to beef up its crypto business, eyes 20-30% user growth

Ocugen has a market cap of US$1.66 billion, and a forward P/E one year of -28.60. The 52-week highest and lowest stock prices were US$18.77 and US$0.25, respectively.

The trading volume was 4,134,923 on Sep 10. The OCGN stock soared 132.9 percent YTD.

The cash, cash equivalents, and restricted cash of the company were US$115.8 million in Q2, FY21, compared to US$24.2 million in the quarter ended on December 31, 2020. Its loss from operations came in at US$25.61 million, compared to US$3.36 million in the year-ago quarter.

The company reported a net loss of US$25.95 million or a loss of US$0.13 per share, compared to a loss of US$3.61 million or a loss of 0.19 per share in Q2 of fiscal 2020.

Also Read: Affirm (AFRM), Zscaler (ZS) stocks rally after revenue guidance boost


The BioNTech SE is a biotechnology firm based in Germany. It manufactures patient-specific immunotherapies.

The company plans to file papers for approval of its Covid-19 vaccine for the age group of 5 to 11 years in September.

Its market cap is US$78.90 billion, the P/E Ratio is 17.03, the forward P/E one year is 9.26, and its EPS is US$19.11. The BNTX stock rose by 307.31 percent YTD.

Also Read: Aterian (ATER) & Energy Fuels (UUUU): Two trending stocks on Monday

The 52-week highest and lowest stock prices were US$464.00 and US$58.81, respectively. Its share volume on September 10 was 3,037,842.

The total revenue of the company was €5.30 billion (euros) in Q2, FY21, compared to €41.7 million in the year-ago quarter. Its profit for the period came in at €2.78 billion compared to a loss of €88.3 million in Q2, FY20.

Also Read: Why did Camber (CEI), Sonim (SONM) stocks fly high on Friday?


The healthcare sector has been one of the main focuses of investors in recent days, mainly due to the Covid-19 vaccines. Last Thursday, President Joe Biden said it is mandatory for all private sector companies having over 100 employees to vaccinate fully and regularly test all staff members. The S&P 500 index’s healthcare segment rose 17.01 percent YTD and 5.46% QTD.


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.